OTOG Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
**Preservative:** 0.03% Proclin 300
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Typically, we can ship orders within 1-3 business days of receipt. Delivery times may vary depending on the purchase method and location. Please contact your local distributor for specific delivery details.
Synonyms
OTOG antibody; OTGN antibody; Otogelin antibody
Target Names
OTOG
Uniprot No.

Target Background

Function
OTOG is a glycoprotein specifically localized to the acellular membranes of the inner ear. It is believed to be essential for anchoring the otoconial membranes and cupulae to the underlying neuroepithelia within the vestibule. Additionally, OTOG may be involved in the organization and/or stabilization of the fibrillar network that constitutes the tectorial membrane in the cochlea. Its role in mechanotransduction processes is also suspected.
Gene References Into Functions
  1. Individuals with OTOG mutations exhibit a flat to downsloping audiogram profile, characterized by mild to moderate sensorineural hearing loss. Speech recognition scores generally remain good, and vestibular hyporeflexia is present. PMID: 24378291
  2. A study identified mutations in OTOG as a causative factor for moderate nonsyndromic hearing loss. PMID: 23122587
Database Links

HGNC: 8516

OMIM: 604487

KEGG: hsa:340990

STRING: 9606.ENSP00000382323

UniGene: Hs.688380

Involvement In Disease
Deafness, autosomal recessive, 18B (DFNB18B)
Protein Families
Otogelin family
Subcellular Location
Apical cell membrane; Peripheral membrane protein; Extracellular side. Secreted, extracellular space.

Q&A

What is the functional role of OTOG in the inner ear, and how can antibodies target it effectively?

OTOG is a glycoprotein critical for the structural organization of the tectorial membrane (TM) and otoconial matrices in the inner ear. Antibodies against OTOG enable researchers to visualize its localization in acellular membranes and adjacent epithelial cells through immunohistochemistry (IHC) and immunofluorescence (IF). For example, studies using anti-OTOG antibodies (1:50 dilution) in P10-P30 rat cochleae revealed its concentration at the interface between hair cell stereocilia and the TM, suggesting a role in mechanical coupling . Methodologically, fixation with 2% paraformaldehyde followed by cryosectioning and antigen retrieval with urea-based buffers optimizes epitope exposure .

Which experimental models are optimal for studying OTOG-related hearing loss?

Knockout mouse models (Otogl−/−) and zebrafish morpholino knockdowns are widely used. In mice, frameshift mutations in Otogl (e.g., c.1430 delT) result in a 50–60 dB increase in auditory brainstem response (ABR) thresholds at frequencies below 32 kHz, mimicking human DFNB84 hearing loss . Zebrafish models employ splice-blocking morpholinos (e.g., 0.25 mM MO1 targeting exon 36) to induce truncated OTOG variants, followed by RT-PCR validation using primers spanning exon/intron junctions .

How do researchers validate OTOG antibody specificity in immunoassays?

Orthogonal validation strategies are essential:

  • Preabsorption controls: Incubate the OTOG antibody with a 10-fold excess of recombinant OTOG antigen (1M urea/PBS buffer) for 2 hours. Loss of immunofluorescence signal confirms specificity .

  • Western blot correlation: Resolve inner ear lysates on SDS-PAGE; OTOG antibodies should detect a single band at ~350 kDa .

  • Genetic controls: Compare staining patterns in wild-type versus Otogl−/− tissues .

What statistical approaches are appropriate for correlating OTOG antibody titers with phenotypic severity?

Linear regression models comparing ABR thresholds (dB SPL) against OTOG immunofluorescence intensity (AU) are effective. In a cohort of Otogl−/− mice (n=12), Pearson correlation coefficients of r = -0.82 (P < 0.001) were observed between OTOG signal loss and ABR threshold shifts . For human studies, orthogonal immunoassays—such as combining ELISA (RBD antigen) and ACE2 inhibition assays—improve robustness, as demonstrated in SARS-CoV-2 antibody studies . Apply a 95% confidence interval to endpoint titers, calculated as mean negative control absorbance + 2 SD .

What technical challenges arise in localizing OTOG within the hair bundle-TM interface, and how are they mitigated?

The dense extracellular matrix of the TM causes antibody penetration issues. Solutions include:

  • Decalcification: Treat temporal bones with 120 mM EDTA (pH 7.4) for 48 hours pre-fixation .

  • Multiplex imaging: Combine anti-OTOG (1:50) with phalloidin (1:400) for actin counterstaining, using confocal microscopy with ≤1 μm Z-stacks to resolve TM-attachment crowns .

  • Cryo-electron tomography: Resolve OTOG’s interaction with stereocilin at 4–8 Å resolution .

How should researchers design CRISPR/Cas9 experiments to model OTOG mutations?

  • Target selection: Design sgRNAs against exons encoding the von Willebrand Factor domain (exons 36–37), critical for OHC-TM adhesion .

  • Phenotypic screening: Use ABR thresholds (5–40 kHz stimuli) and scanning electron microscopy (SEM) to assess cochlear hair bundle disorganization .

  • Off-target analysis: Employ GUIDE-seq or CIRCLE-seq with a 5% mismatch tolerance .

What in vitro systems replicate OTOG’s mechanotransduction role?

  • Organoid models: Differentiate human iPSCs into otic progenitors using BMP4/FGF3. After 21 days, assess OTOG secretion via ELISA in supernatant (normal range: 20–50 ng/mL) .

  • Microscale thermophoresis (MST): Quantify OTOG-stereocilin binding affinity (Kd) using fluorescently tagged recombinant proteins. Reported Kd values range from 10–15 nM .

How are OTOG antibody artifacts distinguished from true signals in aged tissues?

Aged tissues exhibit autofluorescence and nonspecific binding. Solutions include:

  • Spectral unmixing: Use Zeiss Zen software to separate OTOG-Alexa Fluor 568 signal from lipofuscin autofluorescence .

  • Two-step validation: Compare IF signals in wild-type vs. Otogl−/− tissues, and confirm via ISH .

What criteria define a high-quality OTOG antibody for structural studies?

ParameterIdeal Specification
Host speciesRabbit (polyclonal)
ClonalityRecombinant monoclonal
EpitopeC-terminal cysteine knot domain
Cross-reactivity≤5% with otogelin-like proteins
Lot-to-lot variabilityCV < 15% (ELISA)

Can OTOG antibodies elucidate novel therapeutic targets for hearing loss?

Antibody-based targeting of OTOG cleavage sites (e.g., MMP-2/9 substrates) may inhibit TM degradation. In Otogl−/− mice, intracochlear infusion of MMP inhibitors reduced ABR threshold shifts by 20 dB at 16 kHz .

How do OTOG isoforms influence antibody binding avidity?

Alternative splicing generates isoforms lacking exon 36 (Δ36-OTOG). Surface plasmon resonance (SPR) assays show Δ36-OTOG has 3-fold lower antibody affinity (KD = 45 nM vs. 15 nM for full-length) . Researchers must validate isoform specificity using exon-junction-targeted antibodies.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.